Floatz logo

112 assets in Nonpapillary Renal Cell Carcinoma

Therapeutic assets addressing Nonpapillary Renal Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Girentuximab
Nonpapillary Renal Cell Carcinoma
Massachusetts General HospitalP3BB (67)
Clostridium Butyricum Miyairi 588
Nonpapillary Renal Cell Carcinoma
City of Hope Medical CenterP3BB (66)
Pazopanib
Nonpapillary Renal Cell Carcinoma
Academic and Community Cancer Research UnitedP4BB (66)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Nonpapillary Renal Cell Carcinoma
Regeneron PharmaceuticalsP2BB (65)
Cabozantinib
Nonpapillary Renal Cell Carcinoma
SWOG Cancer Research NetworkP3BB (64)
Nivolumab
Nonpapillary Renal Cell Carcinoma
Fred Hutchinson Cancer CenterP3BB (64)
Cyclophosphamide
Nonpapillary Renal Cell Carcinoma
City of Hope Medical CenterP3B (63)
Irinotecan
Nonpapillary Renal Cell Carcinoma
M.D. Anderson Cancer CenterP3B (63)
Casdatifan
Nonpapillary Renal Cell Carcinoma
Arcus Biosciences, Inc.P3B (62)
Cediranib
Nonpapillary Renal Cell Carcinoma
Roswell Park Cancer InstituteP3B (62)
Durvalumab
Nonpapillary Renal Cell Carcinoma
AstraZenecaP2B (62)
Ipilimumab
Nonpapillary Renal Cell Carcinoma
SWOG Cancer Research NetworkP3B (62)
Lenvatinib
Nonpapillary Renal Cell Carcinoma
Gruppo Oncologico Italiano di Ricerca ClinicaP3B (62)
Pembrolizumab
Nonpapillary Renal Cell Carcinoma
City of Hope Medical CenterP3B (62)
Everolimus
Nonpapillary Renal Cell Carcinoma
M.D. Anderson Cancer CenterP3B (61)
Sorafenib
Nonpapillary Renal Cell Carcinoma
Fudan UniversityP3B (61)
Axitinib
Nonpapillary Renal Cell Carcinoma
SWOG Cancer Research NetworkP3B (60)
Relatlimab
Nonpapillary Renal Cell Carcinoma
M.D. Anderson Cancer CenterP2B (60)
Zanzalintinib
Nonpapillary Renal Cell Carcinoma
City of Hope Medical CenterP2B (60)
mk-3795
Nonpapillary Renal Cell Carcinoma
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)P2B (58)
Palbociclib
Nonpapillary Renal Cell Carcinoma
Stephanie BergP2B (58)
NKT2152
Nonpapillary Renal Cell Carcinoma
NiKang Therapeutics, Inc.P2B (57)
Recombinant Human Hyaluronidase
Nonpapillary Renal Cell Carcinoma
SWOG Cancer Research NetworkP3B (57)
Sitravatinib
Nonpapillary Renal Cell Carcinoma
M.D. Anderson Cancer CenterP2B (57)
Tivozanib
Nonpapillary Renal Cell Carcinoma
City of Hope Medical CenterP3B (57)
Volrustomig
Nonpapillary Renal Cell Carcinoma
AstraZenecaP3B (57)
Piflufolastat
Nonpapillary Renal Cell Carcinoma
Lantheus Medical ImagingP2/3B (56)
68ga-ny104
Nonpapillary Renal Cell Carcinoma
Peking Union Medical College HospitalP2CCC (55)
Belzutifan
Nonpapillary Renal Cell Carcinoma
M.D. Anderson Cancer CenterP2CCC (55)
Toripalimab
Nonpapillary Renal Cell Carcinoma
Jinling Hospital, ChinaP2CCC (55)
Zirconium Zr 89 Girentuximab Deferoxamine
Nonpapillary Renal Cell Carcinoma
NYU Langone HealthP2CCC (55)
Lispro-Ph20 Component Rhuph20
Nonpapillary Renal Cell Carcinoma
Bristol-Myers SquibbP3CCC (54)
Envafolimab
Nonpapillary Renal Cell Carcinoma
Fudan UniversityP2CCC (53)
Fludarabine
Nonpapillary Renal Cell Carcinoma
M.D. Anderson Cancer CenterP1/2CCC (53)
Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3)] And Anti-[Homo Sapiens Cd274 (Programmed Cell Death 1 Ligand 1, Pdl1, Pd-L1, B7 Homolog 1, B7H1, B7-H1, Pdcd1Lg1)], Humanized Monoclonal Antibody, Bispecific, Bivalent
Nonpapillary Renal Cell Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd.P2CCC (53)
Ivocizumab
Nonpapillary Renal Cell Carcinoma
Fudan UniversityP2CCC (53)
Ivonescimab
Nonpapillary Renal Cell Carcinoma
City of Hope Medical CenterP2CCC (53)
Pucotenlimab
Nonpapillary Renal Cell Carcinoma
Sun Yat-sen UniversityP2CCC (53)
Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta
Nonpapillary Renal Cell Carcinoma
Mayo ClinicP2CCC (53)
Sturlimogene Erparepvec
Nonpapillary Renal Cell Carcinoma
City of Hope Medical CenterP2CCC (53)
Vipivotide Tetraxetan
Nonpapillary Renal Cell Carcinoma
European Organisation for Research and Treatment of Cancer - EORTCP2CCC (53)
Vorolanib
Nonpapillary Renal Cell Carcinoma
Sun Yat-sen UniversityP2CCC (53)
Yivoximab
Nonpapillary Renal Cell Carcinoma
Sun Yat-sen UniversityP2CCC (53)
68ga-nym005
Nonpapillary Renal Cell Carcinoma
Norroy Bioscience Co., LTDP1/2CCC (52)
Psma I&T
Nonpapillary Renal Cell Carcinoma
Centre Leon BerardP1/2CCC (52)
Selenium
Nonpapillary Renal Cell Carcinoma
Mohammed MilhemP1/2CCC (52)
Balstilimab
Nonpapillary Renal Cell Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Benmelstobart
Nonpapillary Renal Cell Carcinoma
RenJi HospitalP2CCC (51)
Botensilimab
Nonpapillary Renal Cell Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Catequentinib
Nonpapillary Renal Cell Carcinoma
RenJi HospitalP2CCC (51)
Showing 1 to 50 of 112 assets
PreviousPage 1 of 3Next